Condition category
Pregnancy and Childbirth
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Background and study aims
The aim of this study is to develop a first trimester predictor test for identifying pregnant women at high risks of various pregnancy complications. These complications include high blood pressure in pregnancy (known as pre-eclampsia), miscarriage (pregnancy loss) and spontaneous pre-term birth (premature delivery from 24 to 36 weeks of pregnancy). This predictor test will measure the levels of specific microRNAs from a blood test. microRNAs are small molecules which contain genetic material that is essential for all known forms of life. They control gene expression and regulate many proteins. High levels of miRNAs have been shown to decrease certain gene expression pathways believed to play a role in the development of a healthy pregnancy. This study may help to identify pregnant women who are at high risk of developing pregnancy complications. The outcome of this study may alter the management of future pregnant women deemed to be at risk of developing these adverse outcomes.

Who can participate?
Pregnant women aged 24 to 43

What does the study involve?
Participants provide blood samples at 8-10 weeks of pregnancy. Also, if the participant chooses to return for NIPT (non-invasive prenatal testing) where a blood test is routinely drawn, a very small volume of blood is also drawn for the purpose of this study. The levels of specific miRNAs are measured. Participants are asked to fill out a questionnaire detailing their pregnancy after 9 months. The history of the pregnancy is then compared to the level of miRNAs in the blood.

What are the possible benefits and risks of participating?
There are no direct benefits to those participating. However, the information obtained from this study may help to identify patients who are at high risks of pre-eclampsia, miscarriage or spontaneous preterm delivery. This may result in a change in the management of pregnant women who are identified at risk of adverse pregnancy, and minimise the risk of complications. Drawing blood for normal screening does not carry any risks and participating in this study is not expected to add any further risks.

Where is the study run from?
The Centre for Reproductive and Genetic Health (UK)

When is the study starting and how long is it expected to run for?
December 2017 to August 2019

Who is funding the study?
The Centre for Reproductive and Genetic Health (UK)

Who is the main contact?
1. Ms Jara Ben-Nagi (scientific)
2. Miss Rabi Odia (public)

Trial website

Contact information



Primary contact

Ms Jara Ben-Nagi


Contact details

230-232 Great Portland Street
United Kingdom



Additional contact

Miss Rabi Odia


Contact details

230-232 Great Portland street
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Measuring levels of maternal cell microRNAs to predict adverse pregnancy outcome: a longitudinal observational study


Study hypothesis

Can levels of maternal microRNAs become a first trimester “predictor” test for identifying high risk of an adverse pregnancy outcome (including pre-eclampsia, miscarriage, etc)?

Ethics approval

Not provided at time of registration

Study design

Single-centre longitudinal observational study

Primary study design


Secondary study design

Longitudinal study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Couples that have successfully conceived


Peripheral blood is drawn from a pregnant patient at 8-10 weeks, the sample undergoes separation/extraction of PBMCs which is stored at -80°C. miRNA isolation, miRNA quantification, reverse transcription, and real-time PCR will be carried out. Patients who have participated in this study are then asked to fill out a questionnaire detailing their pregnancy after 9 months. The history of pregnancy will then be compared to the level of microRNA in peripheral blood.

1. Sample collection: After obtaining patient consent. Peripheral blood from successfully conceived patients at 8-10 weeks will be collected in Heparin tubes (green top) and incubated at room temperature for 1-2 hours
2. Separation of PBMCs from peripheral blood and storage: Separation/extraction of PBMCs will be performed at room temperature using Ficollhypaque density gradient centrifugation. The PBMCs layer will be “pipetted” into tubes containing 1ml of Trizol and stored at -80oC
3. Molecular techniques: miRNA isolation, miRNA quantification, reverse transcription, and real-time PCR will be performed by igenomix UK
4. Analysis, statistics and reporting: Will be performed by Igenomix UK scientific staff
5. Follow up: Collection of patient birth and adverse outcomes will be conducted by CRGH. Once the agreed endpoint is reached, the sample IDs will be unblinded and the results shared between CRGH and Igenomix UK in preparation for publication

Intervention type



Drug names

Primary outcome measure

Levels of specific miRNAs isolated from maternal peripheral blood mononuclear cells (PBMCs) in 8-10-week pregnant patients, measured by real-time PCR using TaqMan probes after reverse transcription

Secondary outcome measures

Pregnancy outcome assessed using a questionnaire after 9 months

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

Successfully pregnant healthy females aged between 24 and 43

Participant type

Healthy volunteer

Age group




Target number of participants


Participant exclusion criteria

Under 24 and over 43 years old females who are pregnant

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

The Centre for Reproductive and Genetic Health
230-232 Great Portland Street
United Kingdom

Sponsor information


Centre for Reproductive and Genetic Health

Sponsor details

230-232 Great Portland Street
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type

Hospital/treatment centre

Funder name

Centre for Reproductive and Genetic Health

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal

IPD sharing statement
The datasets generated during and/or analysed during the current study are/will be available upon request from the Centre for Reproductive and Genetics Health ( Data will be available upon completion of the study for a minimum of 5 years. Data will be accessed via an internal shared drive. Access to the shared drive has a designated username and password. The access will only be to the designated research members via an NHS secure web if receiving party also has access to this and password protected. This will be shared with iGenomix UK and only be available upon request. Consent will be obtained from the patients. The data will only contain participants' internal reg number and is password protected.

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes